



Salzburg
Cancer
Research
Institute

5th SALZBURG BREAST CANCER TALK 08. – 09.03.2024

MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY

FRIDAY, 8th MARCH

12:30 – 13:30	Welcome & Business Lunch	
13:30 – 13:35	Introduction	Richard Greil (Salzburg)
13:35 – 15:45	Combination Strategies <i>Chair: Gabriel Rinnerthaler & Simon Gampenrieder</i>	
13:35	Immunotherapy in breast cancer: An overview of current strategies and perspectives	Richard Greil (Salzburg)
14:00	Immune checkpoint inhibitor + anti HER2	Gabriel Rinnerthaler (Salzburg)
14:25	Immune checkpoint inhibitor + ADC	Peter Schmid (London, online)
14:50	Dissecting tumor microenvironment, one cell at a time	Zlatko Trajanoski (Innsbruck)
15:15 – 15:45	Panel Discussion <i>Moderator: Richard Greil (Salzburg)</i>	all speakers
15:45 – 16:15	Coffee Break	
16:15 – 18:30	Novel Therapeutic Approaches <i>Chair: Gabriel Rinnerthaler & Marleen Kok</i>	
16:15	Optimizing breast cancer immunotherapy	Marleen Kok (Amsterdam)
16:40	NK cell targeted therapy	Eric Vivier (Marseille, online)
17:05	CAR T-Cells	Niels Schaft (Erlangen)
17:30	Targeting the microbioma to improve immunotherapy efficacy	Laurence Zitvogel (Paris, online)
17:55 – 18:30	Panel Discussion <i>Moderator: Richard Greil (Salzburg)</i>	all speakers
19:00	Dinner	

SATURDAY, 9th MARCH

08:30 – 10:15	Metabolism & Immunogenicity <i>Chair: Fritz Aberger & Richard Greil</i>	
08:30	2-hydroxyglutarate and other metabolites*	Iosifina Foskolou (Amsterdam)
09:05	The role of tumor-associated macrophages in breast cancer*	Emanuela Romano (Paris)
09:40	Abscopal effect – true or overrated?*	Udo Gaipl (Erlangen)
10:15 – 10:45	Coffee Break	
10:45 – 13:00	Biomarker <i>Chair: Simon Gampenrieder & Roberto Salgado</i>	
10:45	TILs vs PDL1: What is the best pragmatic approach in daily practices?	Roberto Salgado (Antwerp)
11:10	MHC class I loss	Barbara Seliger (Halle)
11:35	Tertiary lymphoid structures	Karen Willard-Gallo (Brussels)
12:00	Immune cell composition	Giampaolo Bianchini (Milano, online)
12:25 – 12:55	Panel Discussion <i>Moderator: Richard Greil (Salzburg)</i>	all speakers
12:55 – 13:00	Closing Remarks	Richard Greil (Salzburg)
13:00 – 14:00	Business Lunch & Farewell	

Hotel Gersbergalm
Gersberg 37
5020 Salzburg

www.gersbergalm.at



Prof. Richard Greil MD

Head of the IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria

Prof. Gabriel Rinnerthaler MD

IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer, Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria

Prof. Simon P. Gampenrieder MD

IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer, Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria

Prof. Peter Schmid FRCP MD PhD

Centre Lead, Centre for Experimental Cancer Medicine, Director, Breast Cancer, St Bartholomew, Hospital London, London, United Kingdom

Prof. Dipl.-Ing. Dr. Zlatko Trajanoski

Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria

Marleen Kok MD PhD

Medical Oncologist and Groupleader Tumor biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Prof. Eric Vivier DVM PhD

Professor, Aix Marseille Univ, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Scientific Director- Innate Pharma Research Labs and President-Paris-Saclay Cancer Cluster, Marseille, France

Prof. Dr. Niels Schaft PhD

Research Group Leader of the RNA-based Immunotherapy group, Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Prof. Laurence Zitvogel MD PhD

Gustave Roussy Comprehensive Cancer Institute, Villejuif, France, Université Paris Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France, INSERM U1015, Villejuif, France

Prof. Dr. Fritz Aberger

Molecular Cancer and Stem Cell Research, Lab Department of Molecular Biology, University of Salzburg, Cancer Cluster Salzburg (CCS), Salzburg, Austria

Dr. Iosifina Foskolou

Group Leader at Sanquin Research, Amsterdam, The Netherlands

Emanuela Romano MD PhD

Medical Director, Center for Cancer Immunotherapy, Department of Oncology, INSERM U932, Institut Curie, Paris, France

Prof. Dr. Udo Gaipl

Head of Translational Radiobiology, Universitätsklinikum Erlangen, Department of Radiation Oncology, Erlangen, Germany

Dr. Roberto Salgado

Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium; Division of Research, Peter Mac Callum Cancer Center, Melbourne, Australia

Prof. Dr. Barbara Seliger

Director of the Institute for Medical Immunology, Martin Luther University, Medical Faculty, Halle, Germany

Karen Willard-Gallo MD PhD

Head Molecular Immunology Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

Giampaolo Bianchini MD

Associate Professor – Università Vita-Salute San Raffaele Head Breast Cancer Group - Department of Medical Oncology, Head clinical translational and immunotherapy research, Ospedale San Raffaele, Milano, Italy

Organization:

Richard Greil, Gabriel Rinnerthaler, Simon P. Gampenrieder

Salzburg Cancer Research Institute (SCRI) with

Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR)

www.limcr.at and

Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)

www.cccit.at

in cooperation with the

Cancer Cluster Salzburg | www.cancercluster-salzburg.at and AGMT gemeinnützige GmbH | www.agmt.at


This event has been accredited with
11 DFP credits



Salzburg
Cancer
Research
Institute



CCCIT
Center for
Clinical Cancer
and Immunology Trials




LIMCR
Laboratory for
Immunological and
Molecular Cancer Research



CANCER
CLUSTER
SALZBURG
www.cancercluster-salzburg.at



AGMT
Austrian Group • Medical • Tumor Therapy

Kindly supported by:  AstraZeneca

and:

